Sources of Pharmacokinetic Variability

Two patients given the same dose of the same drug can reach very different concentrations, because the processes of absorption, distribution, metabolism, and excretion differ from person to person and over time. Understanding these sources of variability explains why fixed dosing is unreliable for some drugs and why measured concentrations can add information.

Definition

Pharmacokinetic variability is the differences in the concentration-time profile achieved by a given dose, arising from interindividual and intraindividual differences in absorption, distribution, metabolism, and excretion and summarised through variation in clearance and volume of distribution.

Scope

This topic surveys the determinants of between-patient and within-patient variability in drug exposure: genetic differences in metabolising enzymes and transporters, organ function (especially renal and hepatic), age and body composition, drug-drug and drug-food interactions, disease states, and adherence. It frames variability through clearance and volume of distribution, the parameters that translate dose into concentration. It is a conceptual reference, not guidance on adjusting any individual's dose.

Core questions

• Which physiological and genetic factors most strongly alter clearance and volume of distribution?
• How do organ impairment and age shift drug exposure?
• When does variability translate into clinically meaningful differences in concentration?
• How do drug interactions and disease change a patient's handling of a drug over time?

Key concepts

• Clearance and volume of distribution as the parameters of variability
• Genetic polymorphism of enzymes and transporters
• Renal and hepatic function
• Age and body composition
• Drug-drug and drug-food interactions
• Disease-state effects on disposition
• Adherence and within-patient variation

Key theories

Genetic determinants of drug disposition

Inherited polymorphisms in drug-metabolising enzymes and transporters create reproducible differences in clearance, producing recognisable phenotypes (for example poor versus extensive metabolisers) that partly explain why a fixed dose yields variable exposure.

Mechanisms

Dose reaches the systemic circulation through absorption (modified by formulation, gut, and first-pass metabolism), distributes according to body composition and protein binding (volume of distribution), and is removed by metabolism and excretion (clearance). Each step varies between people: enzyme and transporter genotype set metabolic capacity; renal and hepatic function set elimination; age and body composition shift distribution; co-administered drugs induce or inhibit the same enzymes and transporters; and disease can alter any of these. Wilkinson's review traces how genetic and environmental factors converge on metabolism to make drug response variable, and pharmacogenomic work links specific variants to disposition phenotypes. Because exposure equals dose-rate divided by clearance at steady state, variability in clearance maps directly onto variability in concentration.

Clinical relevance

Recognising the sources of variability explains why some drugs require individualised dosing and monitoring and why the same regimen can over- or under-expose different patients. This entry describes the determinants of variable exposure as reference material; it is not a basis for selecting or adjusting a dose for any individual.

Evidence & guidelines

Narrative syntheses in major journals map the principal sources of variability in drug response to metabolism, organ function, interactions, and genetics (Wilkinson, 2005), and pharmacogenomic reviews connect specific inherited variants to disposition (Roden et al., 2011). The PK-PD framework explains how this variability propagates from concentration to effect (Holford & Sheiner, 1981).

History

Clinical observation of idiosyncratic drug responses long predated mechanism; the field of pharmacogenetics emerged in the mid-twentieth century from cases such as variable isoniazid acetylation and prolonged response to succinylcholine. Through the 1990s and 2000s, molecular characterisation of cytochrome P450 enzymes, transporters, and their polymorphisms gave a genetic account of much interindividual variability, integrated with the long-recognised roles of organ function, age, and interactions.

Debates

How much of variable drug response is explained by measurable factors?

Genotype, organ function, age, and interactions account for an important but incomplete share of the variability seen in practice; residual unexplained variation limits how far exposure can be predicted from patient characteristics alone, which is part of the rationale for measuring concentrations.

Key figures

• Grant Wilkinson
• Dan Roden
• Malcolm Rowland
• Lewis Sheiner

Seminal works

• wilkinson-2005
• roden-2011

Frequently asked questions

Why do two patients on the same dose reach different drug concentrations?

Because they differ in how they absorb, distribute, metabolise, and excrete the drug. Differences in metabolising-enzyme genotype, kidney and liver function, age, body composition, co-medications, and disease all change clearance and volume of distribution, and therefore the concentration a given dose produces.

Is pharmacokinetic variability only genetic?

No. Genetics is one important source, but organ function, age, body composition, drug and food interactions, disease state, and adherence all contribute, and some variability remains unexplained by any measured factor.